Related by context. All words. (Click for frequent words.) 83 situ LCIS 75 atypical hyperplasia 74 lobular cancer 74 cervical carcinoma 74 mucinous 73 ductal carcinomas 72 endometrial cancers 72 breast carcinoma 72 ductal breast cancer 72 precursor lesions 71 serous ovarian cancer 71 sarcomatoid 71 advanced adenoma 71 Ductal carcinoma 71 lobular carcinomas 71 invasive ductal 71 renal cell carcinomas 71 prostate cancer CaP 71 advanced adenomas 71 ductal cancer 71 ductal carcinoma 71 invasive carcinoma 71 colorectal carcinoma 71 bladder cancers 71 neoplasm 71 invasive lobular 70 adenomatous polyps 70 Papillary 70 ovarian carcinoma 70 micrometastases 70 breast endometrial 70 adenoma 70 metachronous 70 CIN2 + 69 adenocarcinomas 69 lymph node metastasis 69 PCa 69 nonmelanoma skin cancers 69 nodal metastasis 69 hormone receptor negative 69 node metastases 69 hamartomas 69 liver metastasis 69 oesophageal adenocarcinoma 69 thyroid nodules 69 premalignant lesions 69 atypical lobular hyperplasia 69 pancreatic adenocarcinoma 69 neoplastic 69 SLNB 68 peritoneal carcinomatosis 68 gastric adenocarcinoma 68 prostate carcinoma 68 ductal 68 pT2 68 pulmonary metastases 68 lymph node metastases 68 MGUS 68 neoplasias 68 atypia 68 breast carcinomas 68 intestinal metaplasia 68 leiomyomas 68 epithelial tumors 68 DCIS ductal carcinoma 68 urothelial carcinoma 68 papillary carcinoma 68 metastatic prostate 68 GISTs 68 Basal cell 68 pheochromocytoma 68 MALT lymphoma 68 papillary 68 gastric cancers 68 Squamous 68 anaplastic 68 seminoma 68 colorectal tumors 68 lobular breast cancer 68 HNSCC 68 gastric carcinoma 67 lung metastasis 67 distant metastases 67 situ DCIS 67 squamous cell carcinoma SCC 67 neoplasms 67 urine cytology 67 Radical prostatectomy 67 cervical intraepithelial neoplasia 67 histologic subtype 67 pT3 67 pancreatic lung 67 contralateral breast 67 CIN3 67 distant metastasis 67 malignant growths 67 invasive ductal carcinoma 67 carcinoid 67 neoplasia 67 lymphovascular invasion 67 progesterone receptor negative 67 endometrial carcinoma 67 adenomatous 66 benign breast 66 ADPKD 66 atypical ductal hyperplasia 66 epithelioid 66 carcinoma 66 Carcinoid tumors 66 ductal lobular 66 leiomyoma 66 bowel cancers 66 metastatic lesions 66 basal cell carcinoma BCC 66 locoregional recurrence 66 intestinal polyps 66 Adenocarcinoma 66 endometrial hyperplasia 66 nonmelanoma skin cancer 66 Adenomas 66 recurrent ovarian 66 malignant pleural mesothelioma 66 epithelial ovarian 66 invasive carcinomas 66 invasive lobular carcinoma 66 axillary lymph nodes 66 testicular cancers 66 ASCUS 66 colonic polyps 66 benign noncancerous 66 premalignant 66 malignant lesions 66 pleural mesothelioma 66 differentiated thyroid 66 HER2 overexpression 66 precancerous cervical 66 colorectal adenomas 66 prostate adenocarcinoma 66 prostate pancreatic 66 grade cervical intraepithelial 66 prostate cancers 66 choriocarcinoma 66 oligodendrogliomas 66 polyp recurrence 66 histopathologic examination 66 hormone receptor positive 66 adenocarcinoma 66 uterine ovarian 66 micrometastasis 66 neoadjuvant therapy 66 colorectal adenoma 66 colorectal cancer CRC 66 proximal colon 66 nonalcoholic steatohepatitis NASH 66 malignant prostate 66 bilateral oophorectomy 66 Carcinoma 66 basal cell nevus syndrome 66 colorectal polyp 66 HGPIN 66 NMIBC 65 fibrocystic 65 uterine cervix 65 Endometrial 65 pleomorphic 65 nonsmall cell lung cancer 65 colorectal gastric 65 colorectal neoplasms 65 BRCA1 mutation carriers 65 paraganglioma 65 gynecologic malignancy 65 pancreatic prostate 65 pathologic diagnosis 65 colorectal cancers 65 pelvic lymphadenectomy 65 metaplasia 65 metastases 65 seminomas 65 colorectal polyps 65 carcinoid tumor 65 chlamydial infection 65 extracapsular extension 65 sCJD 65 skeletal metastases 65 breast pancreatic 65 esophageal adenocarcinoma 65 pre malignant lesions 65 atrophic gastritis 65 HER2 expression 65 estrogen receptor negative 65 metastatic lymph nodes 65 malignant neoplasm 65 gastric cardia 65 urothelial cancer 65 malignant polyps 65 lymph node involvement 65 lobular 65 estrogen receptor ER 65 epithelial ovarian cancer 65 paragangliomas 65 nodal metastases 65 adjuvant radiotherapy 65 renal tumors 65 specific antigen PSA 65 fibroadenomas 65 hyperplastic 65 p# mutations 65 neuroendocrine cancers 65 K ras mutations 65 situ CIS 65 cervical lesions 65 B7 H3 65 Cholangiocarcinoma 65 mesotheliomas 65 transitional cell carcinoma 65 malignant nodules 65 histological subtype 65 lymphoproliferative disorders 65 PCNSL 65 bone metastasis 65 locoregional 65 Hurthle cell 65 geographic atrophy 65 diabetes mellitus DM 65 Metastatic breast cancer 65 neoplastic lesions 64 Sezary syndrome 64 distal colon cancer 64 gastrointestinal stromal tumor 64 tumoral 64 nonmetastatic 64 pCR 64 incidentalomas 64 endometrioid 64 B Cell Lymphoma 64 osteosarcomas 64 colorectal adenocarcinoma 64 bone scintigraphy 64 ALK mutations 64 cutaneous melanoma 64 metastatic bladder 64 esophagogastric junction 64 lymphocytic 64 testicular germ cell 64 TIMP 64 Endometrial cancer 64 T1a 64 cervical lymph nodes 64 renal carcinoma 64 malignant cancerous 64 pre cancerous lesion 64 papillary renal cell carcinoma 64 ovarian breast 64 bladder tumors 64 pathologic examination 64 hyperplasia 64 bladder carcinoma 64 rectal cancers 64 pituitary adenomas 64 bladder prostate 64 p# mutation 64 cisplatin resistant 64 squamous cell cancers 64 BRCA deficient 64 CaP 64 astrocytomas 64 perineural invasion 64 thyroid carcinoma 64 ovarian tumors 64 neurofibromas 64 smoldering myeloma 64 breast lesions 64 hepatocellular carcinomas 64 malignancy 64 NP CRNs 64 completely resected 64 precancerous condition 64 squamous 64 PSADT 64 malignant pancreatic 64 serum prostate 64 hepatocellular carcinoma HCC 64 neuroendocrine carcinoma 64 familial pancreatic cancer 64 Adjuvant chemotherapy 64 lobular involution 64 Hashimoto thyroiditis 64 BRAF V#E mutation 64 histologically confirmed 64 HER2 positive cancers 64 adrenocortical cancer 64 prostate colon 64 squamous carcinoma 63 hydronephrosis 63 solar keratosis 63 hyperplastic polyps 63 Inhibin B 63 LCIS 63 unresectable tumors 63 myeloproliferative diseases 63 ABCB1 63 BRCA2 mutations 63 oropharyngeal cancer 63 elevated LDH 63 prostate cancer PCa 63 ductal adenocarcinoma 63 carcinoid tumors 63 clinically localized prostate 63 Colon polyps 63 sentinel lymph node biopsy 63 serum PSA 63 hyperparathyroidism 63 lymphocytosis 63 metastatic malignant 63 eccrine 63 operable breast cancer 63 carcinomas 63 ErbB2 positive 63 Chronic pancreatitis 63 embryonal rhabdomyosarcoma 63 aerodigestive tract 63 radical nephrectomy 63 diffuse gastric 63 cholangiocarcinoma 63 macroalbuminuria 63 hepatocellular carcinoma 63 squamous cell lung cancer 63 BRCA mutation carriers 63 distal colon 63 nonalcoholic steatohepatitis 63 thyroglobulin 63 astrocytoma 63 resistant hormone refractory 63 metastatic gastric 63 lung carcinomas 63 prostate ovarian 63 invasive ductal carcinomas 63 cervical dysplasia 63 Metastases 63 breast tumors 63 metastatic colorectal 63 ovarian lung 63 Leukemias 63 obstructive coronary artery 63 preoperative chemotherapy 63 ovarian pancreatic 63 CIN2 63 parathyroid 63 cervical lymph node 63 meningiomas 63 Squamous cell 63 microvascular disease 63 dysglycemia 63 cell carcinomas 63 HER2 amplification 63 breast uterine 63 benign nodules 63 pancreatic cancers 63 thymoma 63 esophageal cancers 63 prostate carcinomas 63 gadolinium enhanced 63 malignant transformation 63 poorer prognosis 63 polypoid 63 Hepatocellular Carcinoma HCC 63 colorectum 63 pheochromocytomas 63 cytoreduction 63 GSTP1 63 radical prostatectomy RP 63 mammographic density 63 BRCA2 mutation carriers 63 CIN3 + 63 pancreatic colon 63 bladder ovarian 63 scintigraphic 63 HbF 63 cell carcinoma 63 medically inoperable 63 Anaplastic 63 benign polyps 63 neoplastic cells 63 dysplastic nevi 63 hepatic cirrhosis 63 axillary dissection 63 basal cell cancers 63 malignant lymphoma 63 myelomas 63 esophageal carcinoma 63 TRUS biopsy 63 adnexal mass 63 Ductal Carcinoma 63 elevated CRP 63 colorectal lung 63 HER2 positivity 63 biochemical recurrence 62 seminal vesicle invasion 62 penile cancers 62 curative resection 62 lichen planus 62 lymphadenectomy 62 pancreatic carcinoma 62 thromboembolic disease 62 Glioblastoma Multiforme GBM 62 lung pancreatic 62 PIK3CA 62 R0 resection 62 T1c 62 FDG uptake 62 tumor recurrence 62 Uterine fibroids 62 CYT# potent vascular disrupting 62 Wilms tumors 62 pituitary adenoma 62 squamous intraepithelial lesions 62 esophageal squamous cell carcinoma 62 recurrent glioblastoma multiforme 62 progesterone receptor PR 62 pathologic 62 haematopoietic 62 supratentorial 62 mycosis fungoides 62 hypermethylation 62 transferrin saturation 62 invasive ductal breast cancer 62 leukemia AML 62 Metastatic 62 epithelial cancers 62 tumors GIST 62 SUVmax 62 Glioblastoma multiforme GBM 62 catheter angiography 62 fibroadenoma 62 pulmonary metastasis 62 malignant fibrous histiocytoma 62 EUS FNA 62 untreated celiac disease 62 myeloproliferative neoplasms 62 Malignant tumors 62 LHRH receptor positive 62 intravesical therapy 62 salpingo oophorectomy 62 cyclin E 62 colorectal pancreatic 62 H. pylori eradication 62 univariate analysis 62 HBeAg negative 62 tumor histology 62 intraductal 62 Lymph node 62 advanced neoplasia 62 LV dysfunction 62 endometrial 62 Squamous cell carcinomas 62 colorectal neoplasia 62 bronchogenic carcinoma 62 PNET 62 stage IIIA 62 resectable 62 hormonally sensitive 62 endometriosis ovarian cysts 62 peritoneal cancer 62 occult metastases 62 fibrocystic changes 62 oral squamous cell 62 primary hyperparathyroidism 62 axillary node 62 TP# mutations 62 neuroblastoma tumors 62 deCODE BreastCancer 62 nutlin 3a 62 neoadjuvant chemotherapy 62 SPINK1 62 carotid stenosis 62 grade squamous intraepithelial 62 BRAF V#E 62 retroperitoneal 62 Barrett mucosa 62 prostatic hyperplasia 62 endometrial cancer 62 antigen PSA 62 uterine cancers 62 amenorrhoea 62 clinically detectable 62 mesangial 62 hematopoietic cancers 62 leiomyosarcoma 62 proliferative diabetic retinopathy 62 metastatic malignant melanoma 62 lung ovary 62 gestational hypertension 62 oophorectomy 62 thymectomy 62 Carcinomas 62 myelofibrosis polycythemia vera 62 adenomas 62 precancerous tumors 62 recurrent NSCLC 62 inducible nitric oxide synthase 62 TMPRSS2 ERG fusion 62 axillary lymph node 62 ccRCC 62 dysplastic lesions caused 62 #.#ng/ml 62 GNAQ 62 prostate bladder 62 gastrointestinal cancers 62 Renal cell carcinoma 62 hypovitaminosis D 62 cytoreductive surgery 62 orchiectomy 62 germline mutations 62 pelvic lymph nodes 62 Medullary thyroid cancer 62 TIMP 1 62 BRCA2 carriers 62 ischemic lesions 62 breast cancers 62 leukaemias 62 orchitis 61 metastatic tumors 61 estrogen receptor positive 61 hypervascular tumors 61 histologically 61 Thyroid nodules 61 adrenalectomy 61 Leydig cell 61 POAG 61 promoter methylation 61 carcinoembryonic antigen 61 HER2 receptor 61 tumor subtypes 61 Uterine cancer 61 thyrotoxicosis 61 Clusterin 61 nephrogenic 61 gallstone disease 61 basal cell cancer 61 pre cancerous 61 FGFR2 gene 61 liver metastases 61 mediastinal 61 cardiac troponin T 61 disease NAFLD 61 adenomatous polyp 61 MYCN amplification 61 Circulating tumor cells 61 hormone receptor status 61 testicular tumors 61 endoscopic ultrasonography 61 myeloproliferative disorders 61 Barrett esophagus 61 noncancerous prostate 61 breast cancer subtypes 61 radioiodine therapy 61 choroidal neovascularization 61 calculi 61 cervical neoplasia 61 carcinoma HCC 61 TCF#L# 61 leukemia ALL 61 biliary tract cancer 61 sarcosine 61 ERBB2 61 follicular thyroid cancer 61 lymph node removal 61 basal cell carcinomas 61 breast cancer metastasis 61 ependymoma 61 hypermethylated 61 precancerous cervical lesions 61 ovarian endometrial 61 cutaneous squamous cell carcinoma 61 JMML 61 HER2 positive tumors 61 BRCA1 mutations 61 cancerous polyps 61 Glioblastoma Multiforme 61 cTnT 61 cancerous enlargement 61 infiltrating ductal carcinoma 61 medullary thyroid cancer 61 BRCA2 mutation 61 Glioma 61 biochemical relapse 61 Acute myeloid leukemia 61 essential thrombocythemia 61 prostate abnormalities 61 desmoplastic 61 hematuria 61 Acute lymphoblastic leukemia 61 choroidal melanoma 61 pericardial effusion 61 uveal melanoma 61 hamartoma 61 latent tuberculosis infection 61 IDH1 mutation 61 lymphatic tissue 61 squamous cell skin 61 uterine tumors 61 PTPN# 61 NAFLD 61 hepatorenal syndrome 61 lung adenocarcinomas 61 biliary tree 61 fibroma 61 clonogenic 61 localized renal 61 spontaneous bacterial peritonitis 61 Basal Cell 61 Rectal cancer 61 TGFBR1 * 6A 61 mutated BRCA1 61 varices 61 subclinical hyperthyroidism 61 colorectal liver metastases 61 malignant neoplasms 61 pAkt 61 benign prostatic hyperplasia enlarged 61 perimenopausal women 61 #F FDG PET 61 kidney cysts 61 squamous cell carcinomas 61 hepatic fibrosis 61 colon rectal 61 coronary calcification 61 seminal vesicle 61 Benign breast 61 fine needle aspiration 61 neuroblastomas 61 Malignant Melanoma 61 BRCA2 gene mutation 61 lung adenocarcinoma 61 histologic subtypes 61 TNF blocker therapy 61 Cyclin E 61 H pylori 61 mosaicism 61 prostate walnut 61 mRNA expression 61 prognostic indicator 61 thyroid carcinomas 61 HER2 positive metastatic breast 61 FGFR2 61 metastatic pancreatic 61 stage IIIB 61 angiosarcoma 61 precancerous polyp 61 biopsied breast 61 benign proliferative breast 61 lactate dehydrogenase 61 immunohistochemical staining 61 LVNC 61 hypercalciuria 61 lung nodules 61 sentinel nodes 61 subependymal giant cell 61 curable cancers 61 sonographically 61 nonproliferative 61 eosinophilic 61 prostate tumor 61 intraepithelial neoplasia 61 para aortic 61 prognostic factor 61 gastrointestinal stromal tumors GISTs 61 pancreatic endocrine 61 obstructive coronary 61 intrahepatic 61 dysplastic lesions 61 extracapsular 61 postoperative pulmonary 61 metastatic renal 61 isoenzyme 61 PAOD 61 elevated triglyceride levels 61 cancer mCRC 61 pancreatic ovarian 61 perioperative morbidity 61 postoperative morbidity 61 KRAS mutations 61 immunohistochemical analysis 61 metastatic cancer 61 cholelithiasis 61 benign lesions 61 Candida infection 61 hypophosphatemia 61 mammographically 61 systemic scleroderma 61 Venous thromboembolism 61 Prostatitis 61 MMP# 61 BRAF mutation 61 histologies 61 Prognostic factors 61 CP CPPS 61 Gliomas 61 pyelonephritis 61 squamous cell 61 Testicular cancer 61 normal karyotype 61 ovarian colon 61 idiopathic myelofibrosis 61 lymphadenopathy 61 malignant ovarian 61 ALND 61 taxane therapy 61 TMPRSS2 ERG 61 lymphomas leukemias 61 osteolytic 61 KRAS mutation 61 CagA 60 bronchoalveolar lavage 60 varicocele 60 osteoid 60 GIST tumors 60 cytologic 60 surgically resected 60 metastatic RCC 60 bacterial prostatitis 60 IPAH 60 CC genotype 60 neuroendocrine tumors 60 lymph node dissection 60 Heavy menstrual bleeding 60 Sjögren syndrome 60 infiltrative 60 Histopathologic examination 60 extracranial 60 cellularity 60 Pleural mesothelioma 60 clinicopathologic 60 microsatellite instability 60 Nonalcoholic fatty liver 60 endosonography 60 androgen deficiency 60 atherosclerotic lesions 60 prognostic significance 60 malignancies 60 rs# [001] 60 systemic amyloidosis 60 thyroid nodule 60 pleural fluid 60 fallopian tube carcinoma 60 activating mutations 60 cytological 60 metastatic 60 histologic 60 BRAF mutations 60 lung tumors 60 PARP inhibition 60 HRCT 60 secondary hyperparathyroidism 60 ascites 60 BRCA mutations 60 GBM tumors 60 axillary lymph node dissection 60 postoperative pathology 60 response pCR 60 hepatocellular carcinoma liver 60 rs# [002] 60 total thyroidectomy 60 pilocytic astrocytomas 60 castrate resistant 60 molecular subtypes 60 follicular adenoma 60 anterior uveitis 60 genital ulcers 60 Sentinel node biopsy 60 nonmelanoma 60 TGF ß1 60 SGPT 60 lipid abnormalities 60 parathyroid carcinoma 60 Endothelial dysfunction 60 micronuclei 60 castration resistant 60 renal cysts 60 teratoma 60 F FDG PET 60 parous women 60 oncogenic mutations 60 clinicopathological features 60 p# biomarker 60 Nodules 60 nodular 60 ovarian malignancy 60 lymph node enlargement 60 anal lesions 60 gene BRCA2 60 synovial 60 papillary RCC 60 HER2 negative 60 axillary nodes 60 precancers 60 SIADH 60 carcinomatosis 60 chromosomal mutations 60 metastatic prostate cancer 60 metastasis 60 Acute Myeloid Leukaemia AML 60 neovascular 60 prostate cancer CRPC 60 APOL1 60 gastric atrophy 60 serum phosphate 60 papillary thyroid carcinoma 60 hormone refractory prostate 60 Trichomonas vaginalis 60 surgically resectable 60 Immunohistochemical staining 60 intact parathyroid hormone 60 histopathologic diagnosis 60 paraneoplastic 60 myometrium 60 chromosomal instability 60 CD# expression [001] 60 histopathologic 60 Asymptomatic 60 carcinoids 60 chromosomal rearrangement 60 CVD mortality 60 Wilms tumor 60 metastatic renal cell carcinoma 60 chemoresistant 60 alkaline phosphatase ALP 60 Waldenstrom macroglobulinemia 60 relapsed MM 60 deCODE ProstateCancer TM 60 vestibular schwannomas 60 penetrance 60 myelodysplastic syndrome MDS 60 benign growths 60 factor PlGF 60 invasive breast cancer 60 precancer 60 cancerdefine 60 invasive ductal cancer 60 pre cancerous polyps 60 core needle biopsies 60 microalbuminuria 60 radiographic findings 60 basal cell skin 60 benign neoplasms 60 urothelial 60 gastric cancer 60 acute leukemias 60 hepatocellular 60 sentinel lymph nodes 60 Colorectal cancers 60 CMV infection 60 VEGF expression 60 neuroblastoma tumor 60 nodal dissection 60 fungoides 60 HepG2 cells 60 thyrotropin 60 preoperative PSA 60 hepatocellular cancer 60 Barrett esophagus BE 60 Cystatin C 60 GSTM1 60 hepatic steatosis 60 carotid plaques 60 endocrine tumors 60 gastroesophageal junction 60 stratifying patients 60 DNA methylation patterns 60 preoperative staging 60 Legg Calvé Perthes disease 60 periodontal bacteria 60 hepatic metastases 60 intracranial hemorrhage ICH 60 needle aspiration 60 contralateral breast cancer 60 nodular melanoma 60 oesophageal 60 nasopharyngeal carcinoma 60 Epstein Barr virus EBV 60 Aspergillus species 60 angiographically 60 lobules 60 ovarian cancers 60 Mitomycin C 60 epididymal 60 undergoing radical prostatectomy 60 cranial irradiation 60 endocrine therapies 60 urinary bladder cancer 60 autoimmune thyroid 60 metastatic adenocarcinoma 60 ALT elevation 60 genetic syndromes 60 breast ovary 60 PIGF 60 tumors 60 Pulmonary hypertension 60 nonseminoma 60 Brain metastases 60 Peritoneal mesothelioma 60 Pancreatic 60 hereditary hemochromatosis 60 radical cystectomy 60 chronic pancreatitis 60 gastric pancreatic 60 subclinical 60 Cystectomy 60 cytologic examination 60 cervical breast 60 intravenous bisphosphonates 60 trophoblasts 60 castration resistant hormone refractory 60 infarcts 60 allogeneic HSCT 60 GSTT1 60 clinicopathological 60 endocervical 60 EGFR mutations 60 interleukin IL -# 60 Chronic lymphocytic leukemia 59 microscopic hematuria 59 glandular tissue 59 IDH mutations 59 BRCA1 BRCA2 59 subclinical hypothyroidism 59 metastatic lung cancer 59 myeloperoxidase 59 colorectal tumor 59 noncancerous tumors 59 NSCLC tumors 59 methylation markers 59 polycystic kidneys 59 confidence interval #.#-#.# 59 bile duct cancers 59 CDH1 59 carotid artery thickness 59 ERalpha 59 grade gliomas 59 Medulloblastoma 59 histologic findings 59 fibroids endometriosis 59 IV NSCLC 59 gastric mucosa 59 tumor lysis syndrome 59 Prostate specific antigen 59 cytoreductive nephrectomy 59 systolic dysfunction 59 microbleeds 59 aplasia 59 lymphoid tissue 59 choroidal neovascularization CNV 59 Immunohistochemical analysis 59 molar pregnancy 59 transfusion syndrome 59 renal artery stenosis 59 underwent resection 59 TPMT 59 EGFR protein 59 hormone refractory 59 breast abscesses 59 haematologic 59 AAT deficiency 59 IgA deficiency 59 chorioamnionitis 59 immunoreactivity 59 peritoneal fluid 59 noncalcified 59 bacteraemia 59 de ath 59 IGFBP 59 TT genotype 59 FDG PET imaging 59 Helicobacter pylori infection 59 LRP5 59 underwent surgical resection 59 prognostically 59 relapsed ALL 59 frequently benign tumor 59 N. gonorrhoeae 59 histologically proven 59 myeloproliferative disorder 59 meningioma 59 C. trachomatis 59 Acoustic neuromas 59 chromophobe 59 HIV HCV coinfected 59 endometrial kidney 59 radiosensitivity 59 sentinel node 59 gestational diabetes mellitus 59 renal cell carcinoma 59 myelofibrosis MF 59 Lymphocytic 59 bowel polyps 59 colon rectum 59 immunostaining 59 oligodendroglioma 59 redox active